> d ibib abs hitind 1-6

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS <<LOGINID::20100325>>
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20060024365	A1	20060202	US 2005-134633		20050519	
IN 2002MU00697	A	20040529	IN 2002-MU697		20020805	<--
IN 193042	A1	20040626				
IN 2002MU00699	A	20040529	IN 2002-MU699		20020805	<--
IN 2003MU00080	A	20050204	IN 2003-MU80		20030122	
IN 2003MU00082	A	20050204	IN 2003-MU82		20030122	
US 20040096499	A1	20040520	US 2003-630446		20030729	<--
PRIORITY APPLN. INFO.:			IN 2002-MU697	A	20020805	
			IN 2002-MU699	A	20020805	
			IN 2003-MU80	A	20030122	
			IN 2003-MU82	A	20030122	
			US 2003-630446	A2	20030729	

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

INCL 424468000
CC 63-6 (Pharmaceuticals)
IT 149908-53-2, Azimilide 150332-35-7, Pamaqueside 150378-17-9, Indinavir 150829-93-9, Nisamycin 150915-41-6, Perospirone 150977-36-9, Bromelain 151271-08-8, Imidazenil 151272-78-5, Antarelix 151319-34-5, Zaleplon 151581-23-6, Apaxifylline 151767-02-1, Montelukast sodium 152923-56-3, Dacliximab 152981-31-2, Inolimomab 153101-26-9, Regavirumab 153205-46-0, Asimadoline 153438-49-4, Dapitant 153723-34-3, Axinastatin 2 153723-35-4, Axinastatin 3 153858-68-5, Contortrostatin 154039-60-8, Marimastat 154212-56-3, Cosalane 154248-96-1, Iroplact 154277-21-1, Cypemycin 154361-50-9, Capecitabine 154397-77-0, Napsagatran 154612-39-2, Palinavir 155213-67-5, Ritonavir 155233-30-0, Curacin A 155319-91-8, Mangafodipir 155415-08-0, Inogatran 155660-91-6, Bistramide D 155660-92-7, Bistramide k 155773-56-1, Ferristene 155773-57-2, Pegorgotein 156039-69-9, Mixanpril 156250-43-0, Manumycin E 156317-47-4, Manumycin F 156586-89-9, Edrecolomab 156679-34-4, Lenercept 156712-35-5, Galdansetron hydrochloride 156769-21-0, Sanfetrinem 156790-85-1, Variolin B 157078-48-3, Isohomohalichondrin B 157207-83-5,

Bioxalomycin α-2 157857-21-1, Maspin 158792-24-6, Collismycin A 158792-25-7, Collismycin B 159445-63-3, Nateplase 159519-65-0, Pentafuside 161009-41-2 161600-01-7, MCC-555 162341-15-3, Darlucin A 163663-18-1, Protegrin 164325-97-7, Veroxanon 165101-51-9, Becaplermin 168482-36-8, Cryptophycin 8 169494-85-3, Leptin 170861-63-9, JTT-501 171544-35-7, Ferumoxsil 172647-53-9, DRF-2189 172793-30-5 173044-45-6 173046-02-1, Thiocoraline 173940-41-5, Tapgen 174305-65-8, Breflate 177402-92-5, Curiosin 178303-21-4, Ferucarbotran 188364-40-1, CARN 700 189339-64-8 191034-25-0, L 168049 193012-35-0, FK614 196808-24-9, GW 1929 200139-38-4, Suradista 200631-89-6, CRE-16336 202532-75-0 207309-33-9, Motilide 209808-51-5, L 805645 212894-59-2, Pentrozole 213252-19-8, KRP-297 213411-83-7, R 483 213411-84-8, BM-152054 213594-60-6, Balsalazide disodium 222834-30-2, Ragaglitazar) 245075-84-7, LR 90 246252-06-2, Gadolinium texaphyrin 250601-04-8, TAK559 251565-85-2 251572-86-8 308804-09-3, GW 9820 321942-74-9, Phensuccinal 331741-94-7, BMS298585 345631-66-5, Eveminomycin 385390-37-4, Pobilukast edamine 441772-39-0, Isobengazole 441772-43-6, Nagrestip 441772-66-3, Vinxaltine 441774-07-8, Spicamycin D 441774-77-2, Solverol 514172-76-0, Tifurac sodium 516482-86-3, Sermorelin acetate 524675-01-2, CS 011 679809-58-6, Enoxaparin sodium 753015-01-9, Enterostatin 808103-38-0, Cepacidine 812697-78-2, CLX 0940 873298-28-3, NIP 223 875140-52-6 875338-33-3, Tiacrilast sodium 875338-35-5, JTP 20993 892553-42-3, Vitaxin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:317195 CAPLUS <<LOGINID::20100325>>
DOCUMENT NUMBER: 141:405978
TITLE: Antioxidant activity of mangafodipir is not a new finding. Reply
AUTHOR(S): Batteux, Frederic
CORPORATE SOURCE: Laboratoire d'Immunologie, Pavillon Hardy-Hopital Cochin, Paris, 75679, Fr.
SOURCE: Journal of Hepatology (2004), 40(5), 873
CODEN: JOHEEC; ISSN: 0168-8278
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A polemic in response to J.O.G. Karlsson regarding why superoxide dismutase data was not inluded.
CC 1-12 (Pharmacology)
IT 155319-91-8, Mangafodipir
RL: PAC (Pharmacological activity); BIOL (Biological study)
(work has not been quoted because demonstrated mangafodispir SOD like activity was incomplete, did not made any enzyme activity comparisons to other standard SOD mimics and work in field of ischemic heart disease is far from hepatol.)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:317194 CAPLUS <<LOGINID::20100325>>
DOCUMENT NUMBER: 142:127433
TITLE: Antioxidant activity of mangafodipir is not a new finding

AUTHOR(S): Karlsson, Jan Olof G.
CORPORATE SOURCE: Department of Pharmacology, University of Linkoping, Linkoping, Swed.
SOURCE: Journal of Hepatology (2004), 40(5), 872-873
CODEN: JOHEEC; ISSN: 0168-8278
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A polemic in response to Batteux et al. (J. Hepatol. 2003, 39, 765-772) is given. Batteux et al. showed profound in vivo protective effects of mangafodipir (MnDPDP; manganese dipyridoxyl diphosphate) against acetaminophen-induced acute liver failure in mice. They hypothesized that MnDPDP could exert superoxide dismutase activity. However, these authors omitted an important reference by Per Jynge et al. (1999), which provided convincing evidence that MnDPDP and its dephosphorylated metabolite MnPLED (manganese dipyridoxyl ethyldiamine) possessed SOD mimetic activities. It was therefore irrelevant to put up a hypothesis on an already proved phenomenon.

CC 1-12 (Pharmacology)

IT 155319-91-8, Mangafodipir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant activity of mangafodipir is not new finding)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:849436 CAPLUS <<LOGINID::20100325>>
DOCUMENT NUMBER: 137:320346
TITLE: Use of mangafodipir for treating oxidative stress effects and hepatocellular deficiencies
INVENTOR(S): Batteux, Frederic; Weill, Bernard
PATENT ASSIGNEE(S): Universite Rene Descartes (Paris V), Fr.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087579	A1	20021107	WO 2002-FR1457	20020426 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2823977	A1	20021031	FR 2001-5606	20010426 <--
FR 2823977	B1	20061201		
CA 2443838	A1	20021107	CA 2002-2443838	20020426 <--
AU 2002310734	A1	20021111	AU 2002-310734	20020426 <--
EP 1381364	A1	20040121	EP 2002-735506	20020426 <--
EP 1381364	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004526792	T	20040902	JP 2002-584924		20020426 <--
JP 4371197	B2	20091125			
AT 337004	T	20060915	AT 2002-735506		20020426
ES 2271265	T3	20070416	ES 2002-735506		20020426
US 20040142907	A1	20040722	US 2003-475555		20031022 <--
US 7351722	B2	20080401			
PRIORITY APPLN. INFO.:			FR 2001-5606	A	20010426
			WO 2002-FR1457	W	20020426

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses the use of mangafodipir to obtain a medicine for preventive or curative treatment of hepatocellular deficiencies.

IC ICM A61K031-443
ICS A61K033-32; A61P001-16

CC 1-12 (Pharmacology)

IT 155319-91-8, Mangafodipir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mangafodipir for treating oxidative stress effects and hepatocellular deficiencies)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:220008 CAPLUS <<LOGINID::20100325>>

DOCUMENT NUMBER: 135:97585

TITLE: Determination of mangafodipir trisodium and related impurities in bulk substance and pharmaceutical formulation by ion-pair high-performance liquid chromatography

AUTHOR(S): Gjerde, H.; Snotun, A.; Hem, H.; Larsen, K. H.; Dohl, J.

CORPORATE SOURCE: Analytical Sciences R&D, Nycomed Imaging AS, Nydalen, Oslo, 0401, Norway

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2001), 25(1), 109-114
CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The development of an ion-pair liquid chromatog. method for determination of mangafodipir trisodium and related impurities is described. Good resolution was obtained when using a polymeric reverse-phase column and a mobile phase of pH* 10.5 composed by borate buffer, acetonitrile, and tetrabutylammonium hydrogensulfate as ion pair agent. Validation of the method showed good selectivity, precision, accuracy and linearity, and detection limits of 0.1-0.2 μg/mL.

CC 64-3 (Pharmaceutical Analysis)

IT 140678-14-4, Mangafodipir trisodium 155319-91-8, Mangafodipir 190785-32-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of mangafodipir trisodium and related impurities in bulk substance and pharmaceutical formulation by ion-pair high-performance liquid chromatog.)

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:42286 CAPLUS <<LOGINID::20100325>>
DOCUMENT NUMBER: 128:110889
ORIGINAL REFERENCE NO.: 128:21621a,21622a
TITLE: Chelating agents and their metal chelates for treating free radical-induced conditions
INVENTOR(S): Karlsson, Jan Olof Gustav; Jynge, Per; Towart, Robertson
PATENT ASSIGNEE(S): Nycomed Imaging AS, Norway
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9749409	A1	19971231	WO 1997-GB1722	19970624 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258299	A1	19971231	CA 1997-2258299	19970624 <--
CA 2259150	A1	19971231	CA 1997-2259150	19970624 <--
AU 9732689	A	19980114	AU 1997-32689	19970624 <--
AU 720621	B2	20000608		
BR 9709942	A	19990810	BR 1997-9942	19970624 <--
EP 936915	A1	19990825	EP 1997-928369	19970624 <--
EP 936915	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1228703	A	19990915	CN 1997-197438	19970624 <--
HU 9902838	A2	20000128	HU 1999-2838	19970624 <--
HU 9902838	A3	20021028		
NZ 333315	A	20000728	NZ 1997-333315	19970624 <--
JP 2000513351	T	20001010	JP 1998-502558	19970624 <--
JP 4162263	B2	20081008		
AT 225178	T	20021015	AT 1997-928369	19970624 <--
NO 9805916	A	19990125	NO 1998-5916	19981217 <--
US 6258828	B1	20010710	US 1998-213290	19981217 <--

PRIORITY APPLN. INFO.: GB 1996-13182 A 19960624
WO 1997-GB1722 W 19970624

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 128:110889
GI



AB The invention provides the use of a compound I [R1 = H, CH2COR5; R5 = OH, optionally hydroxylated alkoxy, amino, alkylamido; R2 = XYR6; X = bond, C1-3 alkylene or oxoalkylene optionally substituted by R7; Y = bond, O, NR6; R6 = H, COOR8, alkyl, alkenyl, cycloalkyl, aryl, aralkyl optionally substituted by ≥1 groups selected from COOR8, CONR82, NR82, OR8, =NR8, =O, OP(O)(OR8)R7, OSO3M; R7 = OH, optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl; R8 = H, optionally hydroxylated, optionally alkoxylated alkyl; M = H, one equivalent of physiol. tolerable cation; R3 = C1-8 alkylene, 1,2-cycloalkylene, 1,2-arylene; R4 = H, C1-3 alkyl], or a metal chelate or salt thereof, in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of conditions resulting from the presence of free radicals in the human or non-human animal body. Such compds. are particularly effective in relieving symptoms associated with reperfusion of ischemic tissue and in treating or preventing radiation-induced injury.

IC ICM A61K031-675
ICS A61K031-44; A61K031-675; A61K031-00; A61K031-44; A61K031-00

CC 1-12 (Pharmacology)
Section cross-reference(s): 8

IT 7429-91-6D, Dysprosium, chelates, biological studies 7439-89-6D, Iron, chelates, biological studies 7439-96-5D, Manganese, chelates, biological studies 7439-98-7D, Molybdenum, chelates, biological studies 7440-00-8D, Neodymium, chelates, biological studies 7440-02-0D, Nickel, chelates, biological studies 7440-10-0D, Praseodymium, chelates, biological studies 7440-12-2D, Promethium, chelates, biological studies 7440-18-8D, Ruthenium, chelates, biological studies 7440-19-9D, Samarium, chelates, biological studies 7440-27-9D, Terbium, chelates, biological studies 7440-30-4D, Thulium, chelates, biological studies 7440-32-6D, Titanium, chelates, biological studies 7440-45-1D, Cerium, chelates, biological studies 7440-47-3D, Chromium, chelates, biological studies 7440-48-4D, Cobalt, chelates, biological studies 7440-50-8D, Copper, chelates, biological studies 7440-52-0D, Erbium, chelates, biological studies 7440-53-1D, Europium, chelates, biological studies 7440-54-2D, Gadolinium, chelates, biological studies 7440-55-3D, Gallium, chelates, biological studies 7440-60-0D, Holmium, chelates, biological studies 7440-62-2D, Vanadium, chelates, biological studies 7440-64-4D, Ytterbium, chelates, biological studies 7440-66-6D, Zinc, chelates, biological studies 118248-91-2 118248-91-2D, metal chelates 155319-91-8 201539-62-0 201539-66-4 201539-73-3 201539-80-2 201539-86-8 201659-03-2 201659-04-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chelating agents and metal chelates for treating free radical-induced conditions)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:44:48 ON 25 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:45:16 ON 25 MAR 2010
E MANGAFODIPIR/CN
L1 1 S E3

FILE 'CAPLUS' ENTERED AT 11:45:57 ON 25 MAR 2010
L2 17 S L1
L3 6 S L2 AND PY<2005